Threats and Opportunities in Cardiovascular Health - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Threats and Opportunities in Cardiovascular Health
With the cardiovascular disease burden in Europe increasing, policymakers, regulators and other healthcare stakeholders are seeking to raise awareness and lessen the threat. There are also opportunities for pharma companies. The cardiovascular therapeutic area comprises 15% of the total pharmaceutical market and this looks set to grow in the coming years.


Pharmaceutical Technology Europe
Volume 23, Issue 11

Reference

1. European Heart Network, "Cardiovascular Disease Statistics" (2011). http://www.ehnheart.org/, accessed 6 Oct. 2011.

2. European Heart Network, "Children and Obesity and Associated Avoidable Chronic Diseases" (2011), http://www.ehnheart.org/, accessed 6 Oct. 2011.

3. World Heart Federation, "World Heart Day" (2011), http://www.world-heart-federation.org/, accessed 6 Oct. 2011.

4. L. Nainggolan, "FDA Alert: Dronedarone and severe liver injury", http://theheart.org/ (2011), http://www.theheart.org/, accessed 6 Oct. 2011.

5. European Heart Network http://www.ehnheart.org/, accessed 6 Oct. 2011.

6. URCH Publishing, Pharmaceutical Market Trends, 2010–2014 (UK, 2010).

7. EFPIA, "Enlightened self-interest delivering wider insights?", blog post, (2010), http://efpia.blogspot.com/, accessed 6 Oct. 2011.

8. Gonzalo Calvo, "Cardiovascular Biomarkers: A Regulatory Perspective", Presentation from the EMEA/EFPIA Workshop On Biomarkers (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here